JP2018504915A - 尿中の前立腺癌の早期発見のためのｍｉｃｒｏＲＮＡに基づく方法 - Google Patents

尿中の前立腺癌の早期発見のためのｍｉｃｒｏＲＮＡに基づく方法 Download PDF

Info

Publication number
JP2018504915A
JP2018504915A JP2017541256A JP2017541256A JP2018504915A JP 2018504915 A JP2018504915 A JP 2018504915A JP 2017541256 A JP2017541256 A JP 2017541256A JP 2017541256 A JP2017541256 A JP 2017541256A JP 2018504915 A JP2018504915 A JP 2018504915A
Authority
JP
Japan
Prior art keywords
hsa
mir
mirs
expression level
diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017541256A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504915A5 (enExample
Inventor
アニ トムスン ランフェルト
アニ トムスン ランフェルト
クレスチャン フレトスエ ヤコプ
クレスチャン フレトスエ ヤコプ
カリーナ セアアンスン ダルスゴー
カリーナ セアアンスン ダルスゴー
コングスバク ラース
コングスバク ラース
モウリトスン ピーダ
モウリトスン ピーダ
アアントフト トーベン
アアントフト トーベン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exiqon AS
Original Assignee
Exiqon AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exiqon AS filed Critical Exiqon AS
Publication of JP2018504915A publication Critical patent/JP2018504915A/ja
Publication of JP2018504915A5 publication Critical patent/JP2018504915A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017541256A 2015-02-11 2016-02-05 尿中の前立腺癌の早期発見のためのｍｉｃｒｏＲＮＡに基づく方法 Pending JP2018504915A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201500079 2015-02-11
DKPA201500079 2015-02-11
DKPA201500825 2015-12-21
DKPA201500825 2015-12-21
PCT/DK2016/050032 WO2016127998A1 (en) 2015-02-11 2016-02-05 A microrna-based method for early detection of prostate cancer in urine samples

Publications (2)

Publication Number Publication Date
JP2018504915A true JP2018504915A (ja) 2018-02-22
JP2018504915A5 JP2018504915A5 (enExample) 2019-02-28

Family

ID=55435920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017541256A Pending JP2018504915A (ja) 2015-02-11 2016-02-05 尿中の前立腺癌の早期発見のためのｍｉｃｒｏＲＮＡに基づく方法

Country Status (6)

Country Link
US (1) US10400288B2 (enExample)
EP (1) EP3256602B1 (enExample)
JP (1) JP2018504915A (enExample)
CA (1) CA2976577C (enExample)
ES (1) ES2749651T3 (enExample)
WO (1) WO2016127998A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019220759A1 (ja) * 2018-05-17 2019-11-21 Ｓｔｅｍｃｅｌｌ株式会社 がんの分析方法、がんの分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体
JPWO2021049671A1 (enExample) * 2019-09-09 2021-03-18
WO2022209943A1 (ja) * 2021-03-29 2022-10-06 東レ株式会社 生体試料中のマイクロｒｎａの検出方法、中性アミノ酸の塩酸塩の組成物および容器
JP2023113680A (ja) * 2019-05-31 2023-08-16 医薬資源研究所株式会社 疾患・体質の分析方法、疾患・体質の分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016134727A1 (en) 2015-02-27 2016-09-01 Exiqon A/S A microrna-based method for assessing the prognosis of a prostate cancer patient
WO2018049506A1 (en) * 2016-09-14 2018-03-22 Ontario Institute For Cancer Research (Oicr) Mirna prostate cancer marker
CN106834470A (zh) * 2017-02-17 2017-06-13 张灏 miRNA在制备癌症诊断试剂盒中的用途
WO2018159750A1 (ja) * 2017-03-02 2018-09-07 第一三共株式会社 オピオイド薬の治療有効性を予測するためのｍｉｃｒｏＲＮＡバイオマーカー
CN107488734B (zh) * 2017-10-10 2019-11-05 广州医科大学附属第二医院 miR-19a-3p在制备前列腺癌骨转移诊断试剂和治疗药物中的应用
CN107663541A (zh) * 2017-10-31 2018-02-06 温州医科大学 一种用于诊断原发性肝癌的特异性生物标志物及其筛选方法与应用
US20210147944A1 (en) * 2018-04-10 2021-05-20 Unity Health Toronto Methods for monitoring and treating prostate cancer
CN108424962B (zh) * 2018-05-25 2021-08-03 中国人民解放军陆军军医大学 系膜增生性肾小球肾炎的miRNA检测标志物及其诊断试剂盒
CN109112109A (zh) * 2018-07-27 2019-01-01 浙江大学 一种骨髓间充质干细胞外泌体的改造方法
EP3699300A1 (en) * 2019-02-22 2020-08-26 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Seminal mirnas as non-invasive biomarkers for the diagnosis and/or prognosis of prostate cancer
JP2022524382A (ja) 2019-03-15 2022-05-02 エムアイアール サイエンティフィック，エルエルシー 前立腺がんを予測するための方法およびその使用
EP3719144A1 (en) * 2019-04-05 2020-10-07 Fundación para la Investigación Biomédica del Hospital Universitario de la Paz (FIBHULP) Mir-151a-3p as an universal endogenous control for exosome cargo normalization
CN111118165B (zh) * 2020-03-04 2023-04-07 朱伟 一种与前列腺癌辅助诊断相关的血清miRNA标志物及其应用
CN112094910B (zh) * 2020-09-25 2023-03-24 无锡市中医医院 一种用于前列腺癌患病风险评估的miRNA标志物
CN112795657A (zh) * 2021-03-22 2021-05-14 中国农业大学 miRNA在制备诊断或辅助诊断哺乳动物前列腺癌症产品中的应用
KR102550113B1 (ko) * 2021-05-28 2023-07-03 주식회사 시스바이오젠 전립선암 진단용 바이오마커 및 이의 용도
CN114045344B (zh) * 2021-12-09 2024-12-17 觅瑞（杭州）生物科技有限公司 前列腺癌诊断用尿液miRNA标志物、诊断试剂及试剂盒
ES2995178A1 (es) * 2023-07-31 2025-02-07 Servicio Andaluz De Salud Biomarcadores y método de diagnóstico de la diabetes monogénica en adultos jóvenes portadores de alelos HNF1A deletéreos

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011080315A1 (en) * 2009-12-30 2011-07-07 Febit Holding Gmbh Mirna fingerprint in the diagnosis of prostate cancer
CN103882118A (zh) * 2014-02-13 2014-06-25 绍兴市人民医院 用于检测前列腺癌的miRNAs
US20140235469A1 (en) * 2009-05-22 2014-08-21 Asuragen, Inc. Mirna biomarkers of prostate disease
US20140309130A1 (en) * 2013-04-15 2014-10-16 Norgen Biotek Corporation Use of MicroRNAs for Screening and Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia
WO2015190584A1 (ja) * 2014-06-12 2015-12-17 東レ株式会社 前立腺がんの検出キット又はデバイス及び検出方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455199B2 (en) 2007-09-14 2013-06-04 The Ohio State University Research Foundation MicroRNA expression in human peripheral blood microvesicles and uses thereof
EP3118334A1 (en) 2009-11-04 2017-01-18 DiamiR, LLC Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
EP2771487A1 (en) * 2011-10-27 2014-09-03 Asuragen, INC. Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors
US9944991B2 (en) 2012-11-02 2018-04-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies
WO2014085906A1 (en) 2012-12-03 2014-06-12 St. Michael's Hospital Microrna biomarkers for prostate cancer
EP3000895A1 (en) 2014-09-26 2016-03-30 Integragen A method for predicting responsiveness to a treatment with an EGFR inhibitor
WO2016115312A1 (en) * 2015-01-14 2016-07-21 Ohio State Innovation Foundation Mirna-based predictive models for diagnosis and prognosis of prostate cancer
WO2016134727A1 (en) 2015-02-27 2016-09-01 Exiqon A/S A microrna-based method for assessing the prognosis of a prostate cancer patient

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140235469A1 (en) * 2009-05-22 2014-08-21 Asuragen, Inc. Mirna biomarkers of prostate disease
WO2011080315A1 (en) * 2009-12-30 2011-07-07 Febit Holding Gmbh Mirna fingerprint in the diagnosis of prostate cancer
US20150337393A1 (en) * 2009-12-30 2015-11-26 Comprehensive Biomarker Center Gmbh miRNA FINGERPRINT IN THE DIAGNOSIS OF PROSTATE CANCER
US20140309130A1 (en) * 2013-04-15 2014-10-16 Norgen Biotek Corporation Use of MicroRNAs for Screening and Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia
CN103882118A (zh) * 2014-02-13 2014-06-25 绍兴市人民医院 用于检测前列腺癌的miRNAs
WO2015190584A1 (ja) * 2014-06-12 2015-12-17 東レ株式会社 前立腺がんの検出キット又はデバイス及び検出方法

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019220759A1 (ja) * 2018-05-17 2019-11-21 Ｓｔｅｍｃｅｌｌ株式会社 がんの分析方法、がんの分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体
JPWO2019220759A1 (ja) * 2018-05-17 2021-07-15 Ｓｔｅｍｃｅｌｌ株式会社 がんの分析方法、がんの分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体
JP2023113680A (ja) * 2019-05-31 2023-08-16 医薬資源研究所株式会社 疾患・体質の分析方法、疾患・体質の分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体
JP2025029004A (ja) * 2019-05-31 2025-03-05 医薬資源研究所株式会社 疾患・体質の分析方法、疾患・体質の分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体
JPWO2021049671A1 (enExample) * 2019-09-09 2021-03-18
JP7660898B2 (ja) 2019-09-09 2025-04-14 Ｃｒａｉｆ株式会社 マイクロｒｎａを含む体液抽出物
WO2022209943A1 (ja) * 2021-03-29 2022-10-06 東レ株式会社 生体試料中のマイクロｒｎａの検出方法、中性アミノ酸の塩酸塩の組成物および容器

Also Published As

Publication number Publication date
EP3256602B1 (en) 2019-09-04
US20180030542A1 (en) 2018-02-01
US10400288B2 (en) 2019-09-03
ES2749651T3 (es) 2020-03-23
EP3256602A1 (en) 2017-12-20
CA2976577A1 (en) 2016-08-18
WO2016127998A1 (en) 2016-08-18
CA2976577C (en) 2024-11-19

Similar Documents

Publication Publication Date Title
US10400288B2 (en) MicroRNA-based method for early detection of prostate cancer in urine samples
Zhi et al. The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma
Kang et al. Identification of circulating miRNA biomarkers based on global quantitative real-time PCR profiling
Wu et al. Next‐generation sequencing of microRNAs for breast cancer detection
Augello et al. MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma
Torres et al. Selection and validation of endogenous controls for microRNA expression studies in endometrioid endometrial cancer tissues
EP2281903B1 (en) METHOD FOR EVALUATION OF CANCER BY USING miRNA CANCER MARKER
US20110160290A1 (en) Use of extracellular rna to measure disease
Saldanha et al. microRNA-10b is a prognostic biomarker for melanoma
Chen et al. Circulating microRNAs as promising tumor biomarkers
JP6769979B2 (ja) マイクロｒｎａに基づく前立腺がん患者の予後評価方法
Frydrychowicz et al. MicroRNA in lung cancer—a novel potential way for early diagnosis and therapy
JP2011501964A (ja) 扁平上皮細胞肺癌の予後予測プロセス
US20220267863A1 (en) Compositions and methods for determining the prognosis of bladder urothelial cancer
MX2010012542A (es) Metodos para evaluar el cancer colorrectal y composiciones para usar en el.
CN110139936A (zh) 口腔癌、咽癌和喉癌的生物标记
Khoshnevisan et al. A significant upregulation of miR-886-5p in high grade and invasive bladder tumors
EP3344770A1 (en) Novel mirna biomarkers and use thereof
Yang et al. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation and clinicopathological features
US8828963B2 (en) Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
Papadaki et al. Diagnostic and therapeutic impact of miR-142, miR-146a, and miR-155 on cutaneous T-cell lymphoma
WO2018130332A1 (en) Mirna's for prognosing cutaneous t-cell lymphoma
WO2010018585A2 (en) Compositions and methods for prognosis of melanoma
EP3115465A1 (en) Improved biomarker set for salivary gland tumor diagnosis
Izquierdo Reyes et al. Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20170804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190115

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200929